By Mill Chart
Last update: Nov 7, 2023
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) was identified as an affordable growth stock by our stock screener. NASDAQ:NBIX is showing great growth, but also scores well on profitability, solvency and liquidity. At the same time it seems to be priced reasonably. We'll explore this a bit deeper below.
To evaluate a stock's growth potential, ChartMill utilizes a Growth Rating on a scale of 0 to 10. This comprehensive assessment considers various growth aspects, including historical and estimated EPS and revenue growth. NASDAQ:NBIX has achieved a 9 out of 10:
ChartMill assigns a proprietary Valuation Rating to each stock. The score is computed by evaluating various valuation aspects, like price to earnings and free cash flow, both absolutely as relative to the market and industry. NASDAQ:NBIX was assigned a score of 6 for valuation:
To gauge a stock's financial health, ChartMill utilizes a Health Rating on a scale of 0 to 10. This comprehensive evaluation encompasses liquidity and solvency, both in absolute terms and in comparison to industry peers. NASDAQ:NBIX has earned a 7 out of 10:
ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:NBIX, the assigned 8 is noteworthy for profitability:
More Affordable Growth stocks can be found in our Affordable Growth screener.
Check the latest full fundamental report of NBIX for a complete fundamental analysis.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
NEUROCRINE BIOSCIENCES INC
NASDAQ:NBIX (4/26/2024, 7:05:57 PM)
After market: 135.99 0 (0%)135.99
-1.77 (-1.28%)
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser.
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of WHAT THE C@H?!, an educational initiative that aims to close the gap...
The economy is looking very strong and the biotech industry even more so, thus consider these top three stocks for strong profits.
The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza.
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation.
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2024 financial results conference call and...
Looking for growth without the hefty price tag? Consider NASDAQ:NBIX.
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to...
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 clinical study to evaluate the safety, tolerability,...
DexCom, Blackstone and Royal Caribbean head this list of five stocks.
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.